How certain enzymes affect immune responses in heart disease
Contribution of novel lysoplasmalogenases enzymes in regulating macrophage immunometabolic responses in cardiovascular disease
This study is looking at how new enzymes called lysoplasmalogenases help control inflammation and fat levels in immune cells that affect heart health, with the hope of finding better ways to manage heart diseases like atherosclerosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11084507 on NIH RePORTER |
What this research studies
This research investigates the role of novel enzymes called lysoplasmalogenases in regulating immune responses related to cardiovascular diseases, particularly atherosclerosis. The study focuses on how these enzymes influence lipid metabolism and inflammation in macrophages, which are key immune cells involved in heart health. By analyzing gene expression and lipid profiles, the research aims to uncover mechanisms that could lead to new therapeutic strategies for managing cardiovascular conditions. Patients may benefit from insights gained about how to better control inflammation and lipid levels in their bodies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with cardiovascular diseases, particularly those with atherosclerosis.
Not a fit: Patients without cardiovascular disease or those with conditions unrelated to lipid metabolism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve heart health by targeting inflammation and lipid metabolism.
How similar studies have performed: Previous research has shown promising results in understanding lipid metabolism and inflammation in cardiovascular diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Fernandez Hernando, Carlos — Yale University
- Study coordinator: Fernandez Hernando, Carlos
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.